To treat mental illness effectively with pharmacological agents, a drug must be able to cross the blood–brain barrier (BBB) at sufficient amounts to provide therapeutic concentrations within brain tissue at a desired target. The challenge of drug delivery to the central nervous system (CNS) has been a longstanding problem, which has resulted in more than 98% of CNS drugs failing to enter the clinical setting because of poor BBB penetration1. This article discusses first how the BBB generally limits drug delivery to the CNS; secondly, the role the BBB plays, if any, in limiting antidepressants access to the CNS; and, finally, general strategies to bypass the BBB in new drug development for mental illness.
Feature| June 01 2013
Crossing the barrier: The role of the blood–brain barrier in treating mental illness
Chris E. Adkins;
Kara R. Barber;
Biochem (Lond) (2013) 35 (3): 4–8.
- Views Icon Views
- PDF LinkPDF
- Share Icon Share
Chris E. Adkins, Kara R. Barber, Paul R. Lockman; Crossing the barrier: The role of the blood–brain barrier in treating mental illness. Biochem (Lond) 1 June 2013; 35 (3): 4–8. doi: https://doi.org/10.1042/BIO03503004
Download citation file: